Next-Gen Pneumococcal Vaccine Race Continues With Merck’s V114 Data

 
• By Mandy Jackson

Merck’s V114 protected against all 15 targeted serotypes in the first two of 16 Phase III studies, but market leader Pfizer’s 20-valent Prevnar 13 successor is on track for a US FDA filing in late 2020.

Evening scene asphalt international race track with starting or end line, digital imaging recomposition background.
Merck is in a race against Pfizer to file a new pneumococcal vaccine

More from Anti-infective

More from Therapy Areas